Angiotensin Converting Enzyme 2 News and Research

RSS

Genomic analysis reveals vulnerability of many animal species to SARS-CoV-2 infection

Humans are not the only species facing a potential threat from SARS-CoV-2, the novel coronavirus that causes COVID-19, according to a new study from the University of California, Davis.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

Bioinformatics identifies key genes and cellular pathways in COVID-19

The COVID-19 pandemic is showing no signs of waning or extinction anytime soon. Now, a new study published on the preprint server bioRxiv* in August 2020 shows a new bioinformatics approach to studying the pathogenesis of this disease, by uncovering the differentially expressed genes (DEGs) and cell signaling pathways that cause the disease characteristics. This will help develop better therapies to counter the effects of these genes.

20 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

Cells lining the nose are key entry point for coronavirus, shows study

Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.

20 Aug 2020

SARS-CoV-2 hijacks antiviral factors to promote infection in human lung cells

Now, a new study published in the preprint server bioRxiv in August 2020 shows that under conditions resembling those in vivo, IFNs may promote efficient viral invasion instead.

20 Aug 2020

Researchers use heparin to block co-receptor for SARS-CoV-2 infection

Researchers at the University of Amsterdam have conducted a study showing that heparan sulfate proteoglycans are important co-receptors that severe acute respiratory syndrome 2 (SARS-CoV-2) requires to infect host cells.

19 Aug 2020

Human microbiome trims mucosal glycans, influencing SARS-CoV-2 infection

An international team of researchers has conducted a study showing that differences in the human microbiome may influence the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

19 Aug 2020

COVID immunity related to how bad you get it

Researchers at Stanford University in California have shown that severely ill patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop significantly higher levels of antibodies against the virus than asymptomatic individuals and outpatients.

18 Aug 2020

Novel receptor protein may hold promise for treating COVID-19

A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.

17 Aug 2020

SARS-CoV-2 poses significant threat to many marine mammal species

A new study conducted by researchers at Dalhousie University in Halifax, Canada, has found that many species of marine mammal are highly vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

SARS-CoV-2 spike pocket is a putative target for antiviral design

In a methodologically rigorous study, researchers from the University of Oxford have recently shown how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein harbors a lipid-binding pocket which modulates the stability of the prefusion trimer and provides conformational shielding from antibodies. Their findings are currently freely available on the bioRxiv* preprint server.

16 Aug 2020

COVID-19 during pregnancy shows no affect on placental structure and pathology

A new study published on the preprint server medRxiv in August 2020 shows that the placenta in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) does not show any signs of abnormality that can be attributed to the infection.

14 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020

Experimental COVID-19 vaccine prevents severe disease in mice

Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.

14 Aug 2020

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

In an exciting new bioRxiv preprint research paper, Chinese researchers describe the development of membrane nanoparticles from ACE2-rich cells with a potent capacity to block the adherence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

13 Aug 2020

Synthetic nanobodies prevent SARS-CoV-2 infection

A team of researchers from the University of California San Francisco has created a powerful nasal spray or inhaler that can provide high-grade protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The report is presently available on the bioRvix* preprint server.

13 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

New model predicts which COVID-19 patients are at higher risk for hospitalization

Cleveland Clinic researchers have developed and validated a risk prediction model (called a nomogram) that can help physicians predict which patients who have recently tested positive for SARS-CoV-2, the virus that causes COVID-19, are at greatest risk for hospitalization.

12 Aug 2020